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Abstract 1 
The initial establishment of lactic acid bacteria (LAB) and bifidobacteria in the newborn and 2 
the role of breast-milk as a source of these microorganisms are not yet well understood. The 3 
establishment of these microorganisms in vaginally delivered breast-fed full-term infants, 4 
and the presence of viable Bifidobacterium in breast-milk was evaluated. In 1 day-old 5 
newborns Enterococcus and Streptococcus were the microorganisms most frequently 6 
isolated, from 10 days of age until 3 months bifidobacteria become the predominant group. 7 
In breast-milk, Streptococcus was the genus most frequently isolated and Lactobacillus and 8 
Bifidobacterium were also obtained. Breast-milk contains viable lactobacilli and 9 
bifidobacteria that might contribute to the initial establishment of the microbiota in the 10 
newborn. 11 
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1. Introduction 1 
Intestinal colonization of the newborn is essential for establishment, maturation and 2 
maintenance of the gut mucosal barrier [1]. There is increasing evidence that this initial 3 
microbial colonization of the intestine has a strong effect on health and specific aberrancies 4 
in this process may predispose to disease later in life [2].  5 
Early colonization begins with facultative anaerobes such as enterobacteria, coliforms and 6 
lactobacilli and continues with anaerobic genera such as Bifidobacterium, Bacteroides, and 7 
Clostridium. Subsequently, feeding practices affect the concentrations of different microbes 8 
[1]. The greatest difference between the microbiota of breast-fed and formula-fed infants lies 9 
in numbers and species composition of bifidobacteria. Indeed, the health-promoting effects of 10 
breast-milk have been linked partly to different bifidogenic factors and more recently to the 11 
presence of lactic acid bacteria (LAB) and bifidobacteria in breast-milk [3-5]. Increasing the 12 
LAB and bifidobacteria levels is a target for infant formulas and the most common approach 13 
to this end has been to include prebiotic compounds. A different approach is the 14 
supplementation with probiotic bacteria, mainly lactobacilli and bifidobacteria. The use of 15 
strains isolated from breast-milk would increase the similarity between breast-milk and infant 16 
formulas. In this context, the genus Bifidobacterium is especially attractive due to its 17 
predominant role in the healthy infant microbiota and its positive effects and safety records. 18 
Several studies have focused on the infant microbiota. However, there is still limited 19 
information on the initial establishment of LAB and bifidobacteria in the newborn and the 20 
role of breast-milk as a source of bacteria for infant gut colonization. Increasing our 21 
understanding on the initial process of establishment of the LAB and bifidobacterial 22 
microbiota will allow the development of strategies to facilitate this colonization process in 23 
formula-fed or preterm infants.   24 
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The aim of the present work was to assess the establishment and development of the LAB 1 
and bifidobacterial microbiota in vaginally delivered, exclusively breast-fed full-term 2 
infants, as well as in their mothers’ milk, during the first 3 months of age. A second aim was 3 
to assess the presence of viable Bifidobacterium strains in breast-milk.  4 
 5 
2. Materials and Methods 6 
2.1. Samples. 20 mother- infant (full-term) pairs were recruited at the Cabueñes Hospital 7 
(Gijon, Spain). Breast-milk and infant faecal samples were taken at 1, 10, 30 and 90 days of 8 
age. Breast-milk samples were obtained by manual expression. All infants (11 males/9 9 
females) were born at the Neonatology Unit of the Hospital after an uncomplicated 10 
pregnancy. Infants were vaginally delivered, at a gestational age of 39.2 weeks (95% CI; 11 
38.6-39.7) and a birth weight of 3403 grams (95% CI; 3238-3568). None of the mothers or 12 
babies received antibiotic therapy during the sampling period. Five mothers received a single 13 
course pre-partum treatment with ampicillin.  14 
The study was approved by the Ethical Committee of the Regional Asturias Public Health 15 
Service (SESPA) and informed written consent was obtained from the mothers. 16 
2.2. Microbial plate counts. Fresh faecal samples were immediately placed in an anaerobiosis 17 
jar (Anaerocult A system, Merck, Darmstadt, Germany) at the Hospital and transported to the 18 
lab within 2 hours. At reception samples were introduced and processed in an anaerobic 19 
atmosphere (10% H2, 10% CO2 and 80% N2) in a chamber Mac 500 (Don Whitley Scientific, 20 
West Yorkshire, UK). To determine the levels of LAB and bifidobacteria, samples were 21 
serially diluted in a reducing medium containing BHI broth (Merck) supplemented with 0.5% 22 
glucose, 0.5% yeast extract (Merck), 0.25% L-cysteine (Sigma Chemical Co, St. Louis, MO, 23 
USA), 10 µg/L vitamin K1 (Merck) and 0.02 g/L Hemin (sigma). Dilutions were plated in 24 
MRS medium (Difco, Becton, Dickinson and Company, Le Pont de Claix, France) 25 
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supplemented with 0.25 % L-cysteine (Sigma) (MRSc) and incubated in anaerobiosis for 48 1 
hours. Colonies were then counted and isolated for further identification. 2 
2.3. Identity of isolates by partial sequence analysis of the 16S rRNA gene. Colonies 3 
displaying different morphology were differentially counted and isolated from counting plates 4 
for subsequent identification by partial sequence analysis of the 16S rRNA gene. In brief, 5 
isolates were grown overnight in MRSc broth at 37ºC in anaerobic cabinet. Then, 1mL of 6 
cells was harvested by centrifugation and the DNA extracted using the GenElute™ Bacterial 7 
Genomic DNA Kit (Sigma) following manufacturer’s instructions. Partial amplification of the 8 
16S RNA gene and identification of isolates was carried out as previously described [6].  9 
PCR products were purified using the GenElute™ PCR clean-up Kit (Sigma). Automated 10 
sequencing of the PCR products was done at Secugen SL (Madrid, Spain) in an automated 11 
sequencer ABI Prism (Applied Biosystems, Foster City, CA, USA).  12 
2.4. Genetic typing of Bifidobacterium isolates. DNA extracts from the different isolates 13 
identified as Bifidobacterium were used for strain typification by randomly amplified 14 
polymorphic DNA (RAPD) analysis by using the primer (OPA-2) and conditions previously 15 
described [7] 16 
 17 
3.  Results 18 
From day 1 to day 10 of life bacterial counts from infant faeces, obtained in MRSc medium, 19 
raised from about 8.7 to10 log cfu/g and remained stable during the rest of the study (Figure 20 
1). Contrary to this, bacterial levels in breast-milk decreased along the study from 5 log 21 
cfu/mL at day 1 to 3.7 log cfu/mL at 90 days (Figure 1).  22 
240 colonies were picked up from the counting plates, isolated and identified. In faeces from 23 
1 day-old newborns members of the genera Enterococcus and Streptococcus (31% and 28% 24 
of isolates, respectively) were the microorganisms most frequently isolated (Figure 2). Among 25 
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them Enterococcus faecalis and Streptococcus salivarius, respectively, were the main species. 1 
On the other three sampling points (days 10, 30 and 90) microorganisms belonging to 2 
Bifidobacterium were the most frequently found (between 42-59% of isolates depending on 3 
the sampling point) followed by Streptococcus, Lactobacillus and Enterococcus. These 4 
comprise mainly the species Bifidobacterium longum followed by Bifidobacterium breve, 5 
Bifidobacterium bifidum and Bifidobacterium pseudocatenulatum, S. salivarius followed by 6 
Streptococcus vestibularis, Lactobacillus gasseri and E. faecalis, respectively. In most of the 7 
samples (20% of day 1 samples and about 60% of the samples from the other sampling 8 
points) bifidobacteria were the microorganisms present at higher levels in the MRSc plates 9 
and ranged from 7.8 to 10.7 log cfu/g depending on the individual and the sampling time.  10 
With regard to breast-milk, Streptococcus, mainly represented by the species S. salivarius, 11 
was the LAB genus with higher frequency of isolation, ranging from 36 to 65% of isolates 12 
depending on the sampling time. Members of the genus Staphylococcus (a genus not 13 
belonging to LAB) were also found in the culture medium and they constituted between 29 14 
and 50% of the breast-milk isolates. Among them Staphylococcus epidermidis was the most 15 
frequent species. A 5% of the total breast-milk isolates belonged to Lactobacillus genus and 16 
another 5% were Bifidobacterium or relatives which are anaerobic microorganisms that have 17 
not been frequently isolated from breast-milk. Among lactobacilli, L. gasseri was the species 18 
most frequently found. The bifidobacterial strains isolated from breast-milk samples were B. 19 
longum (3 isolates), B. breve (3 isolates) and the Bifidobacterium-like microorganism 20 
Parascardovia denticolens (1 isolate). Their levels ranged between 2.5 and 4.8 log cfu/mL. 21 
Bifidobacterial strains showing identical RAPD profiles were found in samples from breast-22 
milk and the corresponding infant faeces as well as in samples from the same infant at 23 
different sampling times (data not shown). All the strains isolated from different breast milk-24 
infant pairs showed different RAPD profiles. 25 
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4. Discussion 1 
It has been reported that breast-fed infants have less allergies and gastrointestinal infections 2 
than formula fed infants [2]. Therefore, the breast-fed infant microbiota may be considered 3 
the standard of a healthy gut microbiota and needs to be both qualitatively and quantitatively 4 
assessed. LAB and bifidobacteria are often considered as members of a healthy microbiota. 5 
LAB account for less than 1% of the total but bifidobacteria may be predominant members of 6 
the intestinal microbiota in breast-fed infants [8]. This predominance of bifidobacteria appears 7 
to be characteristic of the healthy breast-fed infant gut microbiota and therefore it may have a 8 
key role on later health.  9 
Our results show the initial establishment and development of the intestinal LAB and 10 
bifidobacterial microbiota in breast-fed babies and the presence of these microorganisms and 11 
their evolution in breast-milk. In general, the levels of faecal LAB and bifidobacteria found 12 
are in the range of those previously reported for this human population [9,10].  13 
Breast-milk is difficult to sample and microbiological contamination can never be discarded. 14 
S. salivarius and the non-LAB microorganism Stap. epidermidis, which has been reported to 15 
be a species characteristic of the breast-fed infant [11], were the microorganisms more 16 
frequently isolated. Martin and co-workers [3] isolated LAB from breast milk and showed 17 
that the same LAB strains present in breast-milk are also found in faeces of the corresponding 18 
infant. In a previous study the presence of bifidobacterial DNA in breast-milk was reported 19 
[4]. The question that remained unanswered at that time was whether viable bifidobacteria 20 
were present in breast-milk. Recently, similarly to that found in our study Martin et al. [5] 21 
reported the isolation of bifidobacterial strains from breast-milk samples taken 4-7 days after 22 
delivery, demonstrating the presence of alive bifidobacteria in human milk. These authors  23 
identified B. breve as the most frequently isolated species whilst in our study B. longum was 24 
equally frequent.  25 
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We found that bifidobacterial strains showing the same genetic profiles (RAPD analyses) 1 
were present in breast-milk and the corresponding infant faeces at different sampling points, 2 
suggesting vertical transfer from the mother’s milk to the infant. Identical profiles were not 3 
found among isolates from different infants indicating that during the first months of life the 4 
numerically predominant bifidobacterial populations are individual-specific.  5 
 6 
5. Conclusions 7 
Our results indicate that breast-milk contains viable lactobacilli and bifidobacteria that might 8 
contribute to the establishment and development of the microbiota in the newborn. The 9 
microorganisms isolated in this study may constitute promising strains for their inclusion in 10 
infant formulas. 11 
 12 
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Figure 1. Bacterial counts obtained in MRSc medium for infant faeces (IF) and breast milk 1 
(BM) at the different sampling points assessed.  2 
 3 
 4 
 5 
 6 
Figure 2. Percentages of isolation of different bacterial genera from the plates of MRSc 7 
medium in infant faeces (UP) and breast milk (DOWN) at the different sampling points 8 
analysed. 9 
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